UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 orOR 15(dD) ofOF ~~the~~THE ~~Securities~~SECURITIES ~~Exchange~~EXCHANGE ~~Act~~ACT ofOF 1934

~~Date~~DATE ofOF ~~Report~~REPORT (~~Date~~DATE ofOF ~~earliest~~EARLIEST ~~event~~EVENT ~~reported~~REPORTED): ~~August~~SEPTEMBER 2729, 2009

RAPTOR PHARMACEUTICALS CORP.

(~~Exact~~EXACT ~~name~~NAME ofOF ~~registrant~~REGISTRANT asAS ~~specified~~SPECIFIED inIN ~~its~~ITS ~~charter~~CHARTER)

Delaware	000-50720	98-0379351
DELAWARE	000-50720	98-0379351
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(STATE OR OTHER JURISDICTION OF INCORPORATION)	(COMMISSION FILE NUMBER)	(IRS EMPLOYER IDENTIFICATION NO.)
9 Commercial Blvd., Suite 200, Novato, California 94949
9 COMMERCIAL BLVD., SUITE 200, NOVATO, CALIFORNIA 94949
(Address of principal executive offices and Zip Code)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES AND ZIP CODE)
Registrant’s telephone number, including area code: (415) 382-8111
REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (415) 382-8111
Not applicable
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
(Former name or former address, if changed since last report)

~~Check~~CHECK ~~the~~THE ~~appropriate~~APPROPRIATE ~~box~~BOX ~~below~~BELOW ifIF ~~the~~THE ~~Form~~FORM 8-K ~~filing~~FILING isIS ~~intended~~INTENDED toTO ~~simultaneously~~SIMULTANEOUSLY ~~satisfy~~SATISFY ~~the~~THE ~~filing~~FILING ~~obligation~~OBLIGATION ofOF ~~the~~THE ~~registrant~~REGISTRANT ~~under~~UNDER ~~any~~ANY ofOF ~~the~~THE ~~following~~FOLLOWING ~~provisions~~PROVISIONS (~~see~~SEE ~~General~~GENERAL ~~Instruction~~INSTRUCTION A.2. ~~below~~BELOW):

xo ~~Written~~WRITTEN ~~communications~~COMMUNICATIONS ~~pursuant~~PURSUANT toTO ~~Rule~~RULE 425 ~~under~~UNDER ~~the~~THE ~~Securities~~SECURITIES ~~Act~~ACT (17 CFR 230.425)

o ~~Soliciting~~SOLICITING ~~material~~MATERIAL ~~pursuant~~PURSUANT toTO ~~Rule~~RULE ~~14a~~14A-12 ~~under~~UNDER ~~the~~THE ~~Exchange~~EXCHANGE ~~Act~~ACT (17 CFR 240.~~14a~~14A-12)

o ~~Pre~~PRE-~~commencement~~COMMENCEMENT ~~communications~~COMMUNICATIONS ~~pursuant~~PURSUANT toTO ~~Rule~~RULE ~~14d~~14D-2(bB) ~~under~~UNDER ~~the~~THE ~~Exchange~~EXCHANGE ~~Act~~ACT (17 CFR 240.~~14d~~14D-2(bB))

o ~~Pre~~PRE-~~commencement~~COMMENCEMENT ~~communications~~COMMUNICATIONS ~~pursuant~~PURSUANT toTO ~~Rule~~RULE ~~13e~~13E-4(cC) ~~under~~UNDER ~~the~~THE ~~Exchange~~EXCHANGE ~~Act~~ACT (17 CFR 240.~~13e~~13E-4(cC))

~~Item~~ITEM 81.01 ~~Other~~ENTRY ~~Events~~INTO A MATERIAL DEFINITIVE AGREEMENT.

On August 31, 2009, Raptor Pharmaceuticals Corp. (the “Company”) issued a press release announcing that the Company will hold its 2009 Annual Meeting of Stockholders on Monday, September 28, 2009 at 10 a.m. Pacific Time at its corporate offices at its corporate offices at 9 Commercial Blvd., Suite 200, Novato, California. All of the Company’s stockholders of record as of August 27, 2009 will be eligible to vote at such annual meeting and all of the Company’s stockholders are invited to attend such annual meeting.BACKGROUND

~~The~~ON ~~registration~~SEPTEMBER ~~statement~~29, on2009, ~~Form~~TORREYPINES ~~S-4~~THERAPEUTICS, ~~that~~INC. ~~TorreyPines~~(“TORREYPINES”) ~~Therapeutics~~COMPLETED ITS BUSINESS COMBINATION WITH RAPTOR PHARMACEUTICALS CORP. (“RAP PHARMA”) IN ACCORDANCE WITH THE TERMS OF THAT CERTAIN AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, ~~Inc~~DATED JULY 27, 2009, BY AND AMONG TORREYPINES, ECP ACQUISITION, INC., aA ~~Delaware~~WHOLLY-OWNED ~~corporation~~SUBSIDIARY OF TORREYPINES (“~~TorreyPines~~MERGER SUB”), ~~filed~~AND ~~with~~RAP ~~the~~PHARMA ~~SEC~~(THE ~~that~~“MERGER ~~related~~AGREEMENT”), toPURSUANT ~~the~~TO ~~Merger~~WHICH ~~(as~~MERGER ~~defined~~SUB ~~below~~MERGED WITH AND INTO RAP PHARMA, WITH RAP PHARMA CONTINUING AS THE SURVIVING CORPORATION AND A WHOLLY-OWNED SUBSIDIARY OF TORREYPINES (THE “MERGER”). ~~and~~IMMEDIATELY ~~that~~PRIOR ~~included~~TO aTHE ~~joint~~MERGER ~~proxy~~AND ~~statement/prospectus~~IN ofCONNECTION ~~the~~THEREWITH, ~~Company~~TORREYPINES ~~and~~EFFECTED ~~TorreyPines~~A ~~was~~1-FOR-17 ~~declared~~REVERSE ~~effective~~STOCK bySPLIT ~~the~~OF ~~Securities~~ITS ~~and~~COMMON ~~Exchange~~STOCK ~~Commission~~AND CHANGED ITS CORPORATE NAME TO “RAPTOR PHARMACEUTICAL CORP.” (“~~SEC~~RAPTOR”). onTHE ~~Thursday~~TORREYPINES STOCKHOLDER PROPOSALS REGARDING THE REVERSE STOCK SPLIT, ~~August~~CORPORATE 27NAME CHANGE, AND ISSUANCE OF SHARES OF TORREYPINES’ COMMON STOCK IN THE MERGER AND RESULTING CHANGE OF CONTROL OF TORREYPINES, AMONG OTHERS, WERE APPROVED BY THE STOCKHOLDERS OF TORREYPINES AT THE ANNUAL STOCKHOLDERS MEETING OF TORREY PINES HELD ON SEPTEMBER 28, 2009. THE RAP PHARMA STOCKHOLDER PROPOSAL REGARDING THE ADOPTION OF THE MERGER AGREEMENT, AMONG OTHERS, WAS APPROVED BY THE STOCKHOLDERS OF RAP PHARMA AT THE ANNUAL STOCKHOLDERS MEETING OF RAP PHARMA HELD ON SEPTEMBER 28, 2009. UNLESS THE CONTEXT OTHERWISE REQUIRES, IN THE DISCUSSION SET FORTH IN THIS CURRENT REPORT ON FORM 8-K, ALL REFERENCES HEREIN TO “RAPTOR” REFER TO THE PUBLIC COMPANY (AND ITS WHOLLY-OWNED SUBSIDIARIES) FOLLOWING THE NAME CHANGE AND COMPLETION OF THE MERGER, FORMERLY KNOWN AS TORREYPINES THERAPEUTICS, INC. AND NOW KNOWN AS RAPTOR PHARMACEUTICAL CORP., AND ALL REFERENCES TO “TORREYPINES” REFER TO TORREYPINES THERAPEUTICS, INC., PRIOR TO THE NAME CHANGE AND THE COMPLETION OF THE MERGER. FOLLOWING THE EFFECTIVE TIME OF THE MERGER, THE BUSINESS CONDUCTED BY RAP PHARMA IMMEDIATELY PRIOR TO THE MERGER BECAME PRIMARILY THE BUSINESS CONDUCTED BY RAPTOR.

~~The~~AS ~~full~~A ~~agenda~~RESULT ~~for~~OF ~~the~~THE ~~Company~~MERGER AND IN ACCORDANCE WITH THE MERGER AGREEMENT, EACH SHARE OF RAP PHARMA’sS ~~2009~~COMMON ~~Annual~~STOCK ~~Meeting~~OUTSTANDING ofWAS ~~Stockholders~~CONVERTED isINTO ~~detailed~~THE inRIGHT ~~the~~TO ~~definitive~~RECEIVE ~~joint~~0.2331234 ~~proxy~~SHARES ~~statement/prospectus~~OF RAPTOR’S COMMON STOCK, ~~which~~ON ~~will~~A bePOST ~~mailed~~1-FOR-17 onREVERSE orSPLIT ~~about~~BASIS. ~~September~~EACH OPTION AND WARRANT TO PURCHASE RAP PHARMA’S COMMON STOCK OUTSTANDING AT THE EFFECTIVE TIME OF THE MERGER WAS ASSUMED BY RAPTOR AT THE EFFECTIVE TIME OF THE MERGER, WITH EACH SHARE OF RAP PHARMA’S COMMON STOCK UNDERLYING SUCH OPTIONS AND WARRANTS BEING CONVERTED INTO THE RIGHT TO RECEIVE 0.2331234 SHARES OF RAPTOR’S COMMON STOCK, ON A POST 1-FOR-17 REVERSE SPLIT BASIS, ~~2009~~ROUNDED toDOWN ~~all~~TO ofTHE ~~the~~NEAREST ~~Company~~WHOLE SHARE OF RAPTOR’sS ~~stockholders~~COMMON ofSTOCK. ~~record~~FOLLOWING asTHE ofMERGER, ~~August~~EACH 27SUCH OPTION OR WARRANT HAS A PURCHASE PRICE PER SHARE OF RAPTOR’S COMMON STOCK EQUAL TO THE QUOTIENT OBTAINED BY DIVIDING THE PER SHARE PURCHASE PRICE OF RAP PHARMA’S COMMON STOCK SUBJECT TO SUCH OPTION OR WARRANT BY 0.2331234, ~~2009~~ROUNDED UP TO THE NEAREST WHOLE CENT. DUE TO THE 1-FOR-17 REVERSE STOCK SPLIT, EACH SHARE OF TORREYPINES’ COMMON STOCK, AND WARRANTS AND OPTIONS EXERCISABLE FOR TORREYPINES’ COMMON STOCK, WAS SIMILARLY AFFECTED BY THE 1-FOR-17 REVERSE STOCK SPLIT, RESULTING IN THE CAPITAL STRUCTURE DESCRIBED IN THE NEXT SUCCEEDING PARAGRAPH.

~~The~~AS ~~Company’s~~OF ~~press~~IMMEDIATELY ~~release~~FOLLOWING isTHE ~~attached~~EFFECTIVE ~~hereto~~TIME asOF ~~Exhibit~~THE ~~99.1~~MERGER, ~~and~~FORMER isRAP ~~incorporated~~PHARMA bySTOCKHOLDERS ~~reference~~OWNED ~~into~~APPROXIMATELY ~~this~~95% ~~Item~~OF ~~8.01~~THE inOUTSTANDING ~~its~~COMMON ~~entirety~~STOCK OF RAPTOR AND FORMER TORREYPINES STOCKHOLDERS OWNED APPROXIMATELY 5% OF THE OUTSTANDING COMMON STOCK OF RAPTOR, IN EACH CASE WITHOUT TAKING INTO ACCOUNT ANY OF THE SHARES OF COMMON STOCK OF TORREYPINES OR RAP PHARMA, RESPECTIVELY, THAT WERE ISSUABLE PURSUANT TO OUTSTANDING OPTIONS OR WARRANTS OF TORREYPINES OR RAP PHARMA, RESPECTIVELY, OUTSTANDING AS OF THE EFFECTIVE TIME OF THE MERGER.

~~About~~THE ~~the~~ISSUANCE ~~Proposed~~AND ~~Merger~~EXCHANGE ~~Between~~OF ~~the~~THE ~~Company~~SHARES ~~and~~OF ~~TorreyPines~~RAPTOR’S COMMON STOCK TO THE FORMER STOCKHOLDERS OF RAP PHARMA WAS REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION (“SEC”) ON A REGISTRATION STATEMENT ON FORM S-4 (REG. NO. 333-161424) (THE “REGISTRATION STATEMENT”). PLEASE SEE THE INFORMATION SET FORTH IN THE DEFINITIVE PROXY STATEMENT/PROSPECTUS THAT FORMS A PART OF THE REGISTRATION STATEMENT (THE “DEFINITIVE PROSPECTUS”) IN THE SECTIONS TITLED, “THE MERGER—INTERESTS OF TORREYPINES’ DIRECTORS AND EXECUTIVE OFFICERS IN THE MERGER” AND “INTERESTS OF RAPTOR’S DIRECTORS AND EXECUTIVE OFFICERS IN THE MERGER” FOR A DESCRIPTION OF THE RELATIONSHIPS, OTHER THAN IN RESPECT OF THE MERGER, BETWEEN AND AMONG TORREYPINES, RAPTOR AND THEIR RESPECTIVE DIRECTORS AND OFFICERS. SUCH INFORMATION IS INCORPORATED HEREIN BY REFERENCE.

OnAS ~~July~~OF 27SEPTEMBER 29, 2009, ~~the~~IMMEDIATELY ~~Company~~FOLLOWING ~~entered~~THE ~~into~~CONSUMMATION anOF ~~Agreement~~THE ~~and~~MERGER ~~Plan~~AND ofIN ~~Merger~~CONNECTION ~~and Reorganization (the “Merger Agreement”) with TorreyPines~~THEREWITH, ~~and~~THERE ~~ECP~~WERE ~~Acquisition,~~APPROXIMATELY ~~Inc~~18.,8 aMILLION ~~Delaware~~SHARES ~~corporation~~OF ~~and~~RAPTOR’S ~~wholly-owned~~COMMON ~~subsidiary~~STOCK ofISSUED ~~TorreyPines,~~AND ~~(“Merger~~OUTSTANDING ~~Sub”),~~AND ~~pursuant~~OPTIONS toAND ~~which,~~WARRANTS onEXERCISABLE ~~the~~FOR ~~terms~~A ~~and~~TOTAL ~~subject~~OF ~~to the conditions set forth in the Merger Agreement~~3, ~~TorreyPines will acquire the Company in a stock-for-stock reverse triangular merger (the “Merger”). In the Merger~~321,916 ~~Merger~~SHARES ~~Sub~~OF ~~will~~RAPTOR’S beCOMMON ~~merged with and into the Company~~STOCK, ~~with~~ON ~~the~~A ~~Company~~POST surviving the Merger as a wholly-owned subsidiary of TorreyPines. The foregoing description of the Merger Agreement is not complete and is qualified in its entirety by reference to the Merger AgreementMERGER, aPOST ~~copy of which is attached as Exhibit 2.~~1 ~~to that certain Current Report on Form 8~~-KFOR-17 ~~filed~~REVERSE bySPLIT ~~the Company with the SEC on July 28, 2009~~BASIS. The Merger Agreement has been referenced to provide information regarding its terms; it is not intended to provide any other factual information about the Company or TorreyPines. Such information can be found elsewhere in the public filings the Company and TorreyPines make with the SEC, which are available without charge at www.sec.gov.

~~Not~~TORREYPINES’S aCOMMON ~~Proxy~~STOCKWAS LISTED ~~Statement~~ON THE NASDAQ GLOBAL MARKET, TRADING UNDER THE TICKER SYMBOL “TPTX,” AND WAS SUSPENDED FOR TRADING AS OF THE CLOSE OF BUSINESS ON SEPTEMBER 29, 2009, AND FOLLOWING THE COMPLETION OF THE MERGER, STARTING SEPTEMBER 30, 2009, RAPTOR’S COMMON STOCK BEGAN TRADING ON THE NASDAQ CAPITAL MARKET UNDER THE SYMBOL “RPTP.” PURSUANT TO THE REGULATIONS OF THE NASDAQ CAPITAL MARKET, FOR THE FIRST 20 TRADING DAYS AFTER THE MERGER, THE TICKER SYMBOL WILL BE “RPTPD.”

~~Although~~THE ~~this~~FOREGOING ~~communication~~DESCRIPTION ~~may~~OF beTHE ~~deemed~~TERMS toAND beCONDITIONS ~~solicitation~~OF ~~material~~THE inMERGER ~~respect~~AGREEMENT ofAND ~~the~~RELATED ~~Merger,~~TRANSACTIONS ~~this~~DOES ~~communication~~NOT isPURPORT ~~not~~TO aBE ~~proxy~~COMPLETE ~~statement~~AND orIS aQUALIFIED ~~solicitation~~IN ofITS ~~proxies~~ENTIRETY ~~from~~BY ~~the~~REFERENCE ~~Company’s~~TO orTHE ~~TorreyPines’~~FULL ~~stockholders~~TEXT ~~and~~OF ~~does~~THE ~~not~~MERGER ~~constitute~~AGREEMENT anATTACHED ~~offer~~HERETO ofAS ~~any securities of the Company for sale or a solicitation of an offer to buy or exchange any securities of the Company~~EXHIBIT 2. ~~Any solicitation of proxies will be made only by the definitive joint proxy statement/prospectus that is being mailed on or about September~~ 1, ~~2009~~WHICH toIS ~~all~~INCORPORATED ofHEREIN ~~the~~BY ~~Company’s stockholders of record as of August 27, 2009 as further described herein~~REFERENCE.

~~Additional~~ITEM ~~Information~~5.01 ~~about~~CHANGE ~~the~~IN ~~Merger~~CONTROL ~~and~~OF ~~Where to Find It~~REGISTRANT.

On August 19, 2009, in connection with the Merger, TorreyPines filed a registration statement on Form S-4 with the SEC that included a joint proxy statement/prospectus of the Company and TorreyPines. The registration statement on Form S-4 was declared effective by the SEC on Thursday, August 27, 2009. The definitive joint proxy statement/prospectus included in the Form S-4 will be mailed on or about September 1, 2009 to all of the Company’s stockholders of record as of August 27, 2009 to consider the Merger and other proposals set forth therein. Stockholders of the Company are urged to read the definitive joint proxy statement/prospectus, including all appendices thereto, and any amendments or supplements thereto and other documents filed or to be filed by the Company and TorreyPines because they contain important information about the Company, TorreyPines, the Merger and the proposals to be presented at the Company’s 2009 Annual Meeting of Stockholders. The definitive joint proxy statement/prospectus, and any other documents filed by the Company with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. Copies of the definitive joint proxy statement/prospectus and the Company’s filings with the SEC can also be obtained, without charge, by directing a request to Raptor Pharmaceuticals Corp., 9 Commercial Blvd., Suite 200, Novato, CA 94949, Attention: Kim R. Tsuchimoto, CFO, Fax No. 415-382-1368 or at the email address: ktsuchimoto@raptorpharma.com. Stockholders of the Company are urged to read the definitive joint proxy statement/prospectus and the other relevant materials before making any voting or investment decision with respect to the (A)

~~Merger.~~THE InINFORMATION ~~addition~~SET toFORTH ~~the~~OR ~~registration~~INCORPORATED ~~statement~~BY ~~and~~REFERENCE ~~related~~IN ~~definitive joint proxy statement/prospectus, the Company files annual, quarterly and special reports, proxy statements and other information with the SEC~~ITEM 1.01 ~~Stockholders~~UNDER ofTHE ~~the~~SECTION ~~Company may read and copy any reports~~TITLED, ~~statements~~“BACKGROUND” orOF ~~other~~THIS ~~information~~CURRENT ~~filed~~REPORT byON ~~the Company at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1~~FORM 8-~~800-SEC-0330~~K ~~for~~IS ~~further~~INCORPORATED ~~information~~HEREIN onBY ~~the public reference room~~REFERENCE. The Company’s filings with the SEC are also available to the public from commercial document-retrieval services and at SEC’s website at www.sec.gov, and from investor relations at the Company at the address above.

~~Participants~~ITEM in8.01 ~~the~~OTHER ~~Solicitation~~EVENTS.

~~The~~ON ~~Company~~SEPTEMBER 28, ~~and~~2009, ~~TorreyPines~~RAP ~~and~~PHARMA ~~their~~ISSUED ~~respective~~A ~~directors~~PRESS ~~and~~RELEASE ~~executive~~ANNOUNCING ~~officers~~THE ~~may~~RESULTS beOF ~~deemed~~THE toVOTES beAT ~~participants~~THE inRAP ~~the~~PHARMA’S ~~solicitation~~ANNUAL ofSTOCKHOLDERS’ ~~proxies~~MEETING ~~from~~AND ~~their~~TORREYPINES ~~respective~~ANNUAL ~~stockholders~~STOCKHOLDERS’ ~~in connection with the Merger~~MEETING. ~~Information~~ON ~~regarding~~SEPTEMBER 30, ~~the~~2009, ~~special~~RAPTOR ~~interests~~ISSUED ofA ~~these~~PRESS ~~directors~~RELEASE ~~and~~ANNOUNCING ~~executive~~THE ~~officers~~COMPLETION inOF ~~the~~THE ~~Merger~~MERGER isAND ~~included~~THE inCOMMENCEMENT ~~the~~OF ~~definitive~~RAPTOR’S ~~joint~~COMMON ~~proxy~~STOCK ~~statement/prospectus~~TRADING ~~described~~ON ~~above.~~THE ~~Additional~~NASDAQ ~~information~~CAPITAL ~~regarding~~MARKET, ~~the~~AMONG ~~directors~~OTHER ~~and~~THINGS. ~~executive~~ON ~~officers~~OCTOBER of1, ~~the Company is also included in the Company’s Annual Report~~2009, asRAPTOR ~~amended~~ISSUED onA ~~Form~~PRESS ~~10-K/A~~RELEASE ~~for~~ANNOUNCING ~~the~~THE ~~year~~APPOINTMENT ~~ended~~OF ~~August~~LLEW 31KELTNER, ~~2008~~M.D., ~~and~~PH.D., ~~the~~TO ~~Company~~RAPTOR’sS ~~proxy~~BOARD ~~statement~~OF ~~for its 2008 Annual Meeting of Stockholders~~DIRECTORS, ~~which~~AMONG ~~were~~OTHER ~~filed~~THINGS. ~~with~~COPIES ~~the~~OF ~~SEC~~SUCH onPRESS ~~December~~RELEASES ~~23,~~ARE ~~2008~~ATTACHED ~~and~~HERETO ~~December~~AS 31EXHIBITS 99.1, ~~2007, respectively~~99.2 ~~These~~AND ~~documents~~99.3 ~~are~~TO ~~available~~THIS ~~free~~CURRENT ofREPORT ~~charge~~ON atFORM ~~the~~8-K ~~SEC’s~~AND ~~web~~ARE ~~site~~INCORPORATED atHEREIN ~~www.sec.gov~~BY ~~and from investor relations at the Company at the address above~~REFERENCE.

~~FORWARD-LOOKING~~ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

THE COMPANY AND TORREYPINES CLAIM THE PROTECTION OF THE SAFE HARBOR FOR "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL FACTS. SUCH FORWARD-LOOKING STATEMENTS ARE BASED UPON THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT OF THE COMPANY AND TORREYPINES REGARDING, AMONG OTHER THINGS, THE MERGER, ARE SUBJECT TO RISKS AND UNCERTAINTIES, WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER FROM THE FORWARD-LOOKING STATEMENTS. THE FOLLOWING FACTORS, AMONG OTHERS, COULD CAUSE ACTUAL RESULTS TO DIFFER FROM THOSE SET FORTH IN THE FORWARD-LOOKING STATEMENTS: (1D) THE POTENTIAL VALUE AND OTHER BENEFITS CREATED BY THE PROPOSED MERGER FOR THE COMPANY'S AND TORREYPINES' STOCKHOLDERS; (2) THE EFFICACY, SAFETY AND INTENDED UTILIZATION OF THE COMPANY'S AND TORREYPINES' DRUG CANDIDATES; (3) THE CONDUCT AND RESULTS OF THE COMPANY'S AND TORREYPINES' RESEARCH, DISCOVERY AND PRECLINICAL EFFORTS AND CLINICAL TRIALS; (4) THE COMPANY'S AND TORREYPINES' PLANS REGARDING FUTURE RESEARCH, DISCOVERY AND PRECLINICAL EFFORTS AND CLINICAL ACTIVITIES AND COLLABORATIVE, INTELLECTUAL PROPERTY AND REGULATORY ACTIVITIES; (5) THE PERIOD IN WHICH EACH OF THE COMPANY AND TORREYPINES EXPECTS ITS RESPECTIVE CASH WILL BE AVAILABLE TO FUND ITS RESPECTIVE CURRENT OPERATING PLAN, BOTH BEFORE AND AFTER GIVING EFFECT TO THE MERGER; (6) THE LISTING OF THE SHARES OF TORREYPINES' COMMON STOCK TO BE ISSUED IN THE MERGER ON THE NASDAQ CAPITAL MARKET AND THE NASDAQ STOCK MARKET LLC'S ACCEPTANCE OF THE INITIAL LISTING APPLICATION IN CONNECTION WITH THE MERGER; (7) THE AMOUNT OF NET CASH TORREYPINES ANTICIPATES IT WILL HOLD ON THE CLOSING DATE OF THE MERGER; (8) THE EXCHANGE RATIO, THE AMOUNT OF SHARES TORREYPINES EXPECTS TO ISSUE IN CONNECTION WITH THE MERGER AND THE RATIO FOR THE REVERSE STOCK SPLIT; (9) EACH OF THE COMPANY'S AND TORREYPINES' RESULTS OF OPERATIONS, FINANCIAL CONDITION AND BUSINESSES, AND PRODUCTS AND DRUG CANDIDATES UNDER DEVELOPMENT AND THE EXPECTED IMPACT OF THE PROPOSED MERGER ON THE COMBINED COMPANY'S FINANCIAL AND OPERATING PERFORMANCE; (10) THE EXPECTED TIMING OF CLOSING THE MERGER; AND (11) AND OTHER RISKS REFERENCED FROM TIME TO TIME IN THE COMPANY'S AND TORREYPINES' FILINGS WITH THE SEC AND THOSE FACTORS LISTED IN THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS UNDER "RISK FACTORS." SUCH FORWARD-LOOKING STATEMENTS ARE BASED ON THE COMPANY'S AND TORREYPINES' MANAGEMENT'S CURRENT EXPECTATION, BUT ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THE RESULTS CONTEMPLATED BY THE FORWARD-LOOKING STATEMENTS, INCLUDING, BUT NOT LIMITED TO, THE FOLLOWING: (1) FAILURE OF THE COMPANY'S STOCKHOLDERS TO APPROVE THE MERGER; (2) THE COMPANY'S OR TORREYPINES' INABILITY TO SATISFY THE CONDITIONS OF THE MERGER; (3) THAT THE MERGER IS OTHERWISE DELAYED OR ULTIMATELY NOT CONSUMMATED; (4) THAT THE COMPANY AND TORREYPINES MAY NOT BE ABLE TO COMPLETE THE PROPOSED MERGER; (5) THAT THE NASDAQ STOCK MARKET LLC MAY NOT APPROVE THE LISTING OF THE SHARES OF TORREYPINES COMMON STOCK TO BE ISSUED IN THE MERGER ON THE NASDAQ CAPITAL MARKET OR MAY REJECT THE INITIAL LISTING APPLICATION FILED IN CONNECTION WITH THE MERGER; (6) THAT TORREYPINES' NET CASH AT CLOSING MAY BE LOWER THAN CURRENTLY ANTICIPATED; (7) THAT THE COMPANY'S AND TORREYPINES' DRUG CANDIDATES THAT APPEAR PROMISING IN EARLY RESEARCH AND CLINICAL TRIALS MAY NOT DEMONSTRATE SAFETY AND EFFICACY IN SUBSEQUENT CLINICAL TRIALS; (8) RISKS ASSOCIATED WITH RELIANCE ON COLLABORATIVE PARTNERS FOR FURTHER CLINICAL TRIALS AND OTHER DEVELOPMENT ACTIVITIES; AND (9) RISKS INVOLVED WITH DEVELOPMENT AND COMMERCIALIZATION OF DRUG CANDIDATES.

~~MANY OF THE IMPORTANT FACTORS THAT WILL DETERMINE THESE RESULTS AND VALUES ARE BEYOND THE COMPANY'S AND TORREYPINES' ABILITY TO CONTROL OR PREDICT~~EXHIBITS. STOCKHOLDERS OF THE COMPANY ARE CAUTIONED NOT TO PUT UNDUE RELIANCE ON ANY FORWARD-LOOKING STATEMENTS. EXCEPT AS OTHERWISE REQUIRED BY LAW, THE COMPANY AND TORREYPINES DO NOT INTEND, NOR DOES ANY OF THEM ASSUME ANY OBLIGATION, TO UPDATE ANY FORWARD-LOOKING STATEMENTS. IN EVALUATING THE MERGER AND THE INFORMATION SET FORTH HEREIN, STOCKHOLDERS OF THE COMPANY SHOULD CAREFULLY CONSIDER THE DISCUSSION OF RISKS AND UNCERTAINTIES IN THE SECTION TITLED, "RISK FACTORS" IN THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS.

Item 9.01 Financial Statements and Exhibits.

		FILED
EXHIBIT		HERE	INCORPORATED BY REFERENCE
NO.	EXHIBIT DESCRIPTION	WITH	FORM	FILE NO.	EXHIBIT	FILING DATE	FILED BY
99.1	PRESS RELEASE DATED SEPTEMBER 28, 2009	X
99.2	PRESS RELEASE DATED SEPTEMBER 30, 2009	X
99.3	PRESS RELEASE DATED OCTOBER 1, 2009	X

(d) Exhibits		Description
99.1		Press Release of the Company dated August 31, 2009.

SIGNATURES

~~SIGNATURES~~PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED HEREUNTO DULY AUTHORIZED.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

DATE: OCTOBER 5, 2009

BY: /S/ KIM R. TSUCHIMOTO

NAME:

TITLE:

KIM R. TSUCHIMOTO
CHIEF FINANCIAL OFFICER, TREASURER AND SECRETARY

~~RAPTOR~~ EXHIBIT ~~PHARMACEUTICALS CORP. By: /s/ Kim R. Tsuchimoto Kim R. Tsuchimoto Chief Financial Officer, Treasurer and Secretary Date: August 31, 2009~~INDEX

Exhibit Index

		FILED
EXHIBIT		HERE	INCORPORATED BY REFERENCE
NO.	EXHIBIT DESCRIPTION	WITH	FORM	FILE NO.	EXHIBIT	FILING DATE	FILED BY
99.1	PRESS RELEASE DATED SEPTEMBER 28, 2009	X
99.2	PRESS RELEASE DATED SEPTEMBER 30, 2009	X
99.3	PRESS RELEASE DATED OCTOBER 1, 2009	X

Exhibits		Description
99.1		Press Release of the Company dated August 31, 2009.

Filing Compare · RAPTOR PHARMACEUTICALS CORP.